Characterization of RNA binding and chaperoning activities of HIV-1 Vif protein Importance of the C-terminal unstructured tail

RNA Biology

Volumn 11, Issue 7, 2014, Pages 906-920

  Sleiman, Dona ^a   Bernacchi, Serena ^b   Guerrero, Santiago Xavier ^b   Brachet, Franck ^a   Larue, Valéry ^a   Paillart, Jean Christophe ^b   Tisné, Carine ^a  

^a UNIVERSITÉ PARIS DESCARTES   (France)

^b UNIVERSITÉ DE STRASBOURG   (France)

Author keywords

HIV; Nucleocapsid; RNA chaperone; Unstructured domain; Vif

Indexed keywords

HUMAN IMMUNODEFICIENCY VIRUS 1 VIF PROTEIN; INDOLE; RNA DIRECTED DNA POLYMERASE; TRYPTOPHAN; UNCLASSIFIED DRUG; VIF PROTEIN; CHAPERONE; GAG PROTEIN; NCP7 PROTEIN, HUMAN IMMUNODEFICIENCY VIRUS 1; PROTEIN BINDING; TRANSFER RNA; VIF PROTEIN, HUMAN IMMUNODEFICIENCY VIRUS 1;

AFFINITY CHROMATOGRAPHY; ARTICLE; BINDING SITE; CARBOXY TERMINAL SEQUENCE; CELL INCLUSION; CONTROLLED STUDY; DIMERIZATION; DISSOCIATION CONSTANT; DNA SEQUENCE; HUMAN IMMUNODEFICIENCY VIRUS 2; HYDRODYNAMICS; LIGHT SCATTERING; MASS SPECTROMETRY; MEMBRANE BINDING; NONHUMAN; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; OLIGOMERIZATION; POLYACRYLAMIDE GEL ELECTROPHORESIS; PROTEIN CONFORMATION; PROTEIN DEGRADATION; PROTEIN DOMAIN; PROTEIN FUNCTION; PROTEIN PURIFICATION; PROTEIN SECONDARY STRUCTURE; PROTON NUCLEAR MAGNETIC RESONANCE; REVERSE TRANSCRIPTION; RNA BINDING; RNA SEQUENCE; SIMIAN IMMUNODEFICIENCY VIRUS; VIRION; VIRUS REPLICATION; X RAY CRYSTALLOGRAPHY; CHEMISTRY; CIRCULAR DICHROISM; HUMAN IMMUNODEFICIENCY VIRUS 1; METABOLISM; NUCLEAR MAGNETIC RESONANCE;

BINDING SITES; CIRCULAR DICHROISM; GAG GENE PRODUCTS, HUMAN IMMUNODEFICIENCY VIRUS; HIV-1; MOLECULAR CHAPERONES; NUCLEAR MAGNETIC RESONANCE, BIOMOLECULAR; PROTEIN BINDING; PROTEIN STRUCTURE, SECONDARY; RNA, TRANSFER; VIF GENE PRODUCTS, HUMAN IMMUNODEFICIENCY VIRUS;

EID: 84907582154     PISSN: 15476286     EISSN: 15558584     Source Type: Journal    
DOI: 10.4161/rna.29546     Document Type: Article

References (86)

1. Harris RS, Hultquist JF, Evans DT. The restriction factors of human immunodeficiency virus. J Biol Chem 2012; 287:40875-83; PMID:23043100; http://dx.doi.org/10.1074/jbc.R112.416925
2. Sheehy AM, Gaddis NC, Choi JD, Malim MH. Isolation of a human gene that inhibits HIV-1 infection and is suppressed by the viral Vif protein. Nature 2002; 418:646-50; PMID:12167863; http://dx.doi.org/10.1038/nature00939
3. Mangeat B, Turelli P, Caron G, Friedli M, Perrin L, Trono D. Broad antiretroviral defence by human APOBEC3G through lethal editing of nascent reverse transcripts. Nature 2003; 424:99-103; PMID:12808466; http://dx.doi.org/10.1038/nature01709
4. Mariani R, Chen D, Schröfelbauer B, Navarro F, König R, Bollman B, Münk C, Nymark-McMahon H, Landau NR. Species-specific exclusion of APOBEC3G from HIV-1 virions by Vif. Cell 2003; 114:21-31; PMID:12859895; http://dx.doi.org/10.1016/S0092-8674(03)00515-4
5. Bishop KN, Holmes RK, Malim MH. Antiviral potency of APOBEC proteins does not correlate with cytidine deamination. J Virol 2006; 80:8450-8; PMID:16912295; http://dx.doi.org/10.1128/JVI.00839-06
6. Marin M, Rose KM, Kozak SL, Kabat D. HIV-1 Vif protein binds the editing enzyme APOBEC3G and induces its degradation. Nat Med 2003; 9:1398-403; PMID:14528301; http://dx.doi.org/10.1038/nm946
7. Mehle A, Goncalves J, Santa-Marta M, McPike M, Gabuzda D. Phosphorylation of a novel SOCS-box regulates assembly of the HIV-1 Vif-Cul5 complex that promotes APOBEC3G degradation. Genes Dev 2004; 18:2861-6; PMID:15574592; http://dx.doi.org/10.1101/gad.1249904
8. Yu X, Yu Y, Liu B, Luo K, Kong W, Mao P, Yu XF. Induction of APOBEC3G ubiquitination and degradation by an HIV-1 Vif-Cul5-SCF complex. Science 2003; 302:1056-60; PMID:14564014; http://dx.doi.org/10.1126/science.1089591
9. Jäger S, Kim DY, Hultquist JF, Shindo K, LaRue RS, Kwon E, Li M, Anderson BD, Yen L, Stanley D, et al. Vif hijacks CBF-β to degrade APOBEC3G and promote HIV-1 infection. Nature 2012; 481:371-5; PMID:22190037
10. Zhang W, Du J, Evans SL, Yu Y, Yu XF. T-cell differentiation factor CBF-β regulates HIV-1 Vif-mediated evasion of host restriction. Nature 2012; 481:376-9; PMID:22190036
11. Hultquist JF, Binka M, LaRue RS, Simon V, Harris RS. Vif proteins of human and simian immunodeficiency viruses require cellular CBFβ to degrade APOBEC3 restriction factors. J Virol 2012; 86:2874-7; PMID:22205746
12. Mercenne G, Bernacchi S, Richer D, Bec G, Henriet S, Paillart JC, Marquet R. HIV-1 Vif binds to APOBEC3G mRNA and inhibits its translation. Nucleic Acids Res 2010; 38:633-46; PMID:19910370; http://dx.doi.org/10.1093/nar/gkp1009
13. Kao S, Khan MA, Miyagi E, Plishka R, Buckler-White A, Strebel K. The human immunodeficiency virus type 1 Vif protein reduces intracellular expression and inhibits packaging of APOBEC3G (CEM15), a cellular inhibitor of virus infectivity. J Virol 2003; 77:11398-407; PMID:14557625; http://dx.doi.org/10.1128/JVI.77.21.11398-11407.2003
14. Stopak K, de Noronha C, Yonemoto W, Greene WC. HIV-1 Vif blocks the antiviral activity of APOBEC3G by impairing both its translation and intracellular stability. Mol Cell 2003; 12:591-601; PMID:14527406; http://dx.doi.org/10.1016/S1097-2765(03)00353-8
15. Opi S, Kao S, Goila-Gaur R, Khan MA, Miyagi E, Takeuchi H, Strebel K. Human immunodeficiency virus type 1 Vif inhibits packaging and antiviral activity of a degradation-resistant APOBEC3G variant. J Virol 2007; 81:8236-46; PMID:17522211; http://dx.doi.org/10.1128/JVI.02694-06
16. Goila-Gaur R, Strebel K. HIV-1 Vif, APOBEC, and intrinsic immunity. Retrovirology 2008; 5:51; PMID:18577210; http://dx.doi.org/10.1186/1742-4690-5-51
17. Barraud P, Paillart JC, Marquet R, Tisné C. Advances in the structural understanding of Vif proteins. Curr HIV Res 2008; 6:91-9; PMID:18336256; http://dx.doi.org/10.2174/157016208783885056
18. Batisse J, Guerrero S, Bernacchi S, Sleiman D, Gabus C, Darlix JL, Marquet R, Tisné C, Paillart JC. The role of Vif oligomerization and RNA chaperone activity in HIV-1 replication. Virus Res 2012; 169:361-76; PMID:22728817; http://dx.doi.org/10.1016/j.virusres.2012.06.018
19. Dang Y, Wang X, York IA, Zheng YH. Identification of a critical T(Q/D/E)x5ADx2(I/L) motif from primate lentivirus Vif proteins that regulate APOBEC3G and APOBEC3F neutralizing activity. J Virol 2010; 84:8561-70; PMID:20592083; http://dx.doi.org/10.1128/JVI.00960-10
20. Russell RA, Pathak VK. Identification of two distinct human immunodeficiency virus type 1 Vif determinants critical for interactions with human APOBEC3G and APOBEC3F. J Virol 2007; 81:8201-10; PMID:17522216; http://dx.doi.org/10.1128/JVI.00395-07
21. Schröfelbauer B, Senger T, Manning G, Landau NR. Mutational alteration of human immunodeficiency virus type 1 Vif allows for functional interaction with nonhuman primate APOBEC3G. J Virol 2006; 80:5984-91; PMID:16731937; http://dx.doi.org/10.1128/JVI.00388-06
22. Tian C, Yu X, Zhang W, Wang T, Xu R, Yu XF. Differential requirement for conserved tryptophans in human immunodeficiency virus type 1 Vif for the selective suppression of APOBEC3G and APOBEC3F. J Virol 2006; 80:3112-5; PMID:16501124; http://dx.doi.org/10.1128/JVI.80.6.3112-3115.2006
23. Zhang W, Chen G, Niewiadomska AM, Xu R, Yu XF. Distinct determinants in HIV-1 Vif and human APOBEC3 proteins are required for the suppression of diverse host anti-viral proteins. PLoS One 2008; 3:e3963; PMID:19088851; http://dx.doi.org/10.1371/journal.pone.0003963
24. Pery E, Rajendran KS, Brazier AJ, Gabuzda D. Regulation of APOBEC3 proteins by a novel YXXL motif in human immunodeficiency virus type 1 Vif and simian immunodeficiency virus SIVagm Vif. J Virol 2009; 83:2374-81; PMID:19109396; http://dx.doi.org/10.1128/JVI.01898-08
25. Binka M, Ooms M, Steward M, Simon V. The activity spectrum of Vif from multiple HIV-1 subtypes against APOBEC3G, APOBEC3F, and APOBEC3H. J Virol 2012; 86:49-59; PMID:22013041; http://dx.doi.org/10.1128/JVI.06082-11
26. Zhang H, Pomerantz RJ, Dornadula G, Sun Y. Human immunodeficiency virus type 1 Vif protein is an integral component of an mRNP complex of viral RNA and could be involved in the viral RNA folding and packaging process. J Virol 2000; 74:8252-61; PMID:10954522; http://dx.doi.org/10.1128/JVI.74.18.8252-8261.2000
27. Khan MA, Aberham C, Kao S, Akari H, Gorelick R, Bour S, Strebel K. Human immunodeficiency virus type 1 Vif protein is packaged into the nucleoprotein complex through an interaction with viral genomic RNA. J Virol 2001; 75:7252-65; PMID:11461998; http://dx.doi.org/10.1128/JVI.75.16.7252-7265.2001
28. Hultquist JF, Binka M, LaRue RS, Simon V, Harris RS. Vif proteins of human and simian immunodeficiency viruses require cellular CBFβ to degrade APOBEC3 restriction factors. J Virol 2012; 86:2874-7; PMID:22205746; http://dx.doi.org/10.1128/JVI.06950-11
29. Mehle A, Thomas ER, Rajendran KS, Gabuzda D. A zinc-binding region in Vif binds Cul5 and determines cullin selection. J Biol Chem 2006; 281:17259-65; PMID:16636053; http://dx.doi.org/10.1074/jbc.M602413200
30. Xiao Z, Ehrlich E, Luo K, Xiong Y, Yu XF. Zinc chelation inhibits HIV Vif activity and liberates antiviral function of the cytidine deaminase APOBEC3G. FASEB J 2007; 21:217-22; PMID:17135358; http://dx.doi.org/10.1096/fj.06-6773com
31. Yu Y, Xiao Z, Ehrlich ES, Yu X, Yu XF. Selective assembly of HIV-1 Vif-Cul5-ElonginB-ElonginC E3 ubiquitin ligase complex through a novel SOCS box and upstream cysteines. Genes Dev 2004; 18:2867-72; PMID:15574593; http://dx.doi.org/10.1101/gad.1250204
32. Stanley BJ, Ehrlich ES, Short L, Yu Y, Xiao Z, Yu XF, Xiong Y. Structural insight into the human immunodeficiency virus Vif SOCS box and its role in human E3 ubiquitin ligase assembly. J Virol 2008; 82:8656-63; PMID:18562529; http://dx.doi.org/10.1128/JVI.00767-08
33. Yang S, Sun Y, Zhang H. The multimerization of human immunodeficiency virus type I Vif protein: a requirement for Vif function in the viral life cycle. J Biol Chem 2001; 276:4889-93; PMID:11071884; http://dx.doi.org/10.1074/jbc.M004895200
34. Batisse J, Guerrero SX, Bernacchi S, Richert L, Godet J, Goldschmidt V, Mély Y, Marquet R, de Rocquigny H, Paillart JC. APOBEC3G impairs the multimerization of the HIV-1 Vif protein in living cells. J Virol 2013; 87:6492-506; PMID:23576497; http://dx.doi.org/10.1128/JVI.03494-12
35. Douaisi M, Dussart S, Courcoul M, Bessou G, Lerner EC, Decroly E, Vigne R. The tyrosine kinases Fyn and Hck favor the recruitment of tyrosine-phosphorylated APOBEC3G into vif-defective HIV-1 particles. Biochem Biophys Res Commun 2005; 329:917-24; PMID:15752743; http://dx.doi.org/10.1016/j.bbrc.2005.02.057
36. Bouyac M, Courcoul M, Bertoia G, Baudat Y, Gabuzda D, Blanc D, Chazal N, Boulanger P, Sire J, Vigne R, et al. Human immunodeficiency virus type 1 Vif protein binds to the Pr55Gag precursor. J Virol 1997; 71:9358-65; PMID:9371595
37. Simon JH, Carpenter EA, Fouchier RA, Malim MH. Vif and the p55(Gag) polyprotein of human immunodeficiency virus type 1 are present in colocalizing membrane-free cytoplasmic complexes. J Virol 1999; 73:2667-74; PMID:10074112
38. Goncalves J, Shi B, Yang X, Gabuzda D. Biological activity of human immunodeficiency virus type 1 Vif requires membrane targeting by C-terminal basic domains. J Virol 1995; 69:7196-204; PMID:7474141
39. Kataropoulou A, Bovolenta C, Belfiore A, Trabatti S, Garbelli A, Porcellini S, Lupo R, Maga G. Mutational analysis of the HIV-1 auxiliary protein Vif identifies independent domains important for the physical and functional interaction with HIV-1 reverse transcriptase. Nucleic Acids Res 2009; 37:3660-9; PMID:19369217; http://dx.doi.org/10.1093/nar/gkp226
40. Guo Y, Dong L, Qiu X, Wang Y, Zhang B, Liu H, Yu Y, Zang Y, Yang M, Huang Z. Structural basis for hijacking CBF-β and CUL5 E3 ligase complex by HIV-1 Vif. Nature 2014; 505:229-33; PMID:24402281; http://dx.doi.org/10.1038/nature12884
41. Auclair JR, Green KM, Shandilya S, Evans JE, Somasundaran M, Schiffer CA. Mass spectrometry analysis of HIV-1 Vif reveals an increase in ordered structure upon oligomerization in regions necessary for viral infectivity. Proteins 2007; 69:270-84; PMID:17598142; http://dx.doi.org/10.1002/prot.21471
42. Marcsisin SR, Narute PS, Emert-Sedlak LA, Kloczewiak M, Smithgall TE, Engen JR. On the solution conformation and dynamics of the HIV-1 viral infectivity factor. J Mol Biol 2011; 410:1008-22; PMID:21763503; http://dx.doi.org/10.1016/j.jmb.2011.04.053
43. Reingewertz TH, Benyamini H, Lebendiker M, Shalev DE, Friedler A. The C-terminal domain of the HIV-1 Vif protein is natively unfolded in its unbound state. Protein Eng Des Sel 2009; 22:281-7; PMID:19218568; http://dx.doi.org/10.1093/protein/gzp004
44. Reingewertz TH, Shalev DE, Friedler A. Structural disorder in the HIV-1 Vif protein and interactiondependent gain of structure. Protein Pept Lett 2010; 17:988-98; PMID:20450485; http://dx.doi.org/10.2174/092986610791498876
45. Marcsisin SR, Engen JR. Molecular insight into the conformational dynamics of the Elongin BC complex and its interaction with HIV-1 Vif. J Mol Biol 2010; 402:892-904; PMID:20728451; http://dx.doi.org/10.1016/j.jmb.2010.08.026
46. Bernacchi S, Henriet S, Dumas P, Paillart JC, Marquet R. RNA and DNA binding properties of HIV-1 Vif protein: a fluorescence study. J Biol Chem 2007; 282:26361-8; PMID:17609216; http://dx.doi.org/10.1074/jbc.M703122200
47. Bernacchi S, Mercenne G, Tournaire C, Marquet R, Paillart JC. Importance of the proline-rich multimerization domain on the oligomerization and nucleic acid binding properties of HIV-1 Vif. Nucleic Acids Res 2011; 39:2404-15; PMID:21076154; http://dx.doi.org/10.1093/nar/gkq979
48. Kuciak M, Gabus C, Ivanyi-Nagy R, Semrad K, Storchak R, Chaloin O, Muller S, Mély Y, Darlix JL. The HIV-1 transcriptional activator Tat has potent nucleic acid chaperoning activities in vitro. Nucleic Acids Res 2008; 36:3389-400; PMID:18442994; http://dx.doi.org/10.1093/nar/gkn177
49. Freisz S, Mezher J, Hafirassou L, Wolff P, Nominé Y, Romier C, Dumas P, Ennifar E. Sequence and structure requirements for specific recognition of HIV-1 TAR and DIS RNA by the HIV-1 Vif protein. RNA Biol 2012; 9:966-77; PMID:22767258; http://dx.doi.org/10.4161/rna.20483
50. Henriet S, Richer D, Bernacchi S, Decroly E, Vigne R, Ehresmann B, Ehresmann C, Paillart JC, Marquet R. Cooperative and specific binding of Vif to the 5′ region of HIV-1 genomic RNA. J Mol Biol 2005; 354:55-72; PMID:16236319; http://dx.doi.org/10.1016/j.jmb.2005.09.025
51. Dettenhofer M, Cen S, Carlson BA, Kleiman L, Yu XF. Association of human immunodeficiency virus type 1 Vif with RNA and its role in reverse transcription. J Virol 2000; 74:8938-45; PMID:10982337; http://dx.doi.org/10.1128/JVI.74.19.8938-8945.2000
52. Henriet S, Sinck L, Bec G, Gorelick RJ, Marquet R, Paillart JC. Vif is a RNA chaperone that could temporally regulate RNA dimerization and the early steps of HIV-1 reverse transcription. Nucleic Acids Res 2007; 35:5141-53; PMID:17660191; http://dx.doi.org/10.1093/nar/gkm542
53. Tisné C. Structural bases of the annealing of primer tRNA(3Lys) to the HIV-1 viral RNA. Curr HIV Res 2005; 3:147-56; PMID:15853720; http://dx.doi.org/10.2174/1570162053506919
54. Gabus C, Mazroui R, Tremblay S, Khandjian EW, Darlix JL. The fragile X mental retardation protein has nucleic acid chaperone properties. Nucleic Acids Res 2004; 32:2129-37; PMID:15096575; http://dx.doi.org/10.1093/nar/gkh535
55. Huvent I, Hong SS, Fournier C, Gay B, Tournier J, Carrière C, Courcoul M, Vigne R, Spire B, Boulanger P. Interaction and co-encapsidation of human immunodeficiency virus type 1 Gag and Vif recombinant proteins. J Gen Virol 1998; 79:1069-81; PMID:9603321
56. Khan MA, Akari H, Kao S, Aberham C, Davis D, Buckler-White A, Strebel K. Intravirion processing of the human immunodeficiency virus type 1 Vif protein by the viral protease may be correlated with Vif function. J Virol 2002; 76:9112-23; PMID:12186895; http://dx.doi.org/10.1128/JVI.76.18.9112-9123.2002
57. Yang X, Goncalves J, Gabuzda D. Phosphorylation of Vif and its role in HIV-1 replication. J Biol Chem 1996; 271:10121-9; PMID:8626571; http://dx.doi.org/10.1074/jbc.271.17.10121
58. Gallerano D, Devanaboyina SC, Swoboda I, Linhart B, Mittermann I, Keller W, Valenta R. Biophysical characterization of recombinant HIV-1 subtype C virus infectivity factor. Amino Acids 2011; 40:981-9; PMID:20809132; http://dx.doi.org/10.1007/s00726-010-0725-x
59. Techtmann SM, Ghirlando R, Kao S, Strebel K, Maynard EL. Hydrodynamic and functional analysis of HIV-1 Vif oligomerization. Biochemistry 2012; 51:2078-86; PMID:22369580; http://dx.doi.org/10.1021/bi201738a
60. Janes RW. Bioinformatics analyses of circular dichroism protein reference databases. Bioinformatics 2005; 21:4230-8; PMID:16188926; http://dx.doi.org/10.1093/bioinformatics/bti690
61. Tisné C, Roques BP, Dardel F. The annealing mechanism of HIV-1 reverse transcription primer onto the viral genome. J Biol Chem 2004; 279:3588-95; PMID:14602716; http://dx.doi.org/10.1074/jbc.M310368200
62. Tisné C, Rigourd M, Marquet R, Ehresmann C, Dardel F. NMR and biochemical characterization of recombinant human tRNA(Lys)3 expressed in Escherichia coli: identification of posttranscriptional nucleotide modifications required for efficient initiation of HIV-1 reverse transcription. RNA 2000; 6:1403-12; PMID:11073216; http://dx.doi.org/10.1017/S1355838200000947
63. Mély Y, de Rocquigny H, Sorinas-Jimeno M, Keith G, Roques BP, Marquet R, Gérard D. Binding of the HIV-1 nucleocapsid protein to the primer tRNA(3Lys), in vitro, is essentially not specific. J Biol Chem 1995; 270:1650-6; PMID:7829498; http://dx.doi.org/10.1074/jbc.270.4.1650
64. Tisné C, Roques BP, Dardel F. Heteronuclear NMR studies of the interaction of tRNA(Lys)3 with HIV-1 nucleocapsid protein. J Mol Biol 2001; 306:443-54; PMID:11178904; http://dx.doi.org/10.1006/jmbi.2000.4391
65. Paillart JC, Dettenhofer M, Yu XF, Ehresmann C, Ehresmann B, Marquet R. First snapshots of the HIV-1 RNA structure in infected cells and in virions. J Biol Chem 2004; 279:48397-403; PMID:15355993; http://dx.doi.org/10.1074/jbc.M408294200
66. Marquet R, Baudin F, Gabus C, Darlix JL, Mougel M, Ehresmann C, Ehresmann B. Dimerization of human immunodeficiency virus (type 1) RNA: stimulation by cations and possible mechanism. Nucleic Acids Res 1991; 19:2349-57; PMID:1645868; http://dx.doi.org/10.1093/nar/19.9.2349
67. Paillart JC, Marquet R, Skripkin E, Ehresmann B, Ehresmann C. Mutational analysis of the bipartite dimer linkage structure of human immunodeficiency virus type 1 genomic RNA. J Biol Chem 1994; 269:27486-93; PMID:7961663
68. Cruceanu M, Gorelick RJ, Musier-Forsyth K, Rouzina I, Williams MC. Rapid kinetics of protein-nucleic acid interaction is a major component of HIV-1 nucleocapsid protein's nucleic acid chaperone function. J Mol Biol 2006; 363:867-77; PMID:16997322; http://dx.doi.org/10.1016/j.jmb.2006.08.070
69. Bampi C, Bibillo A, Wendeler M, Divita G, Gorelick RJ, Le Grice SF, Darlix JL. Nucleotide excision repair and template-independent addition by HIV-1 reverse transcriptase in the presence of nucleocapsid protein. J Biol Chem 2006; 281:11736-43; PMID:16500895; http://dx.doi.org/10.1074/jbc.M600290200
70. Simon JH, Southerling TE, Peterson JC, Meyer BE, Malim MH. Complementation of vif-defective human immunodeficiency virus type 1 by primate, but not nonprimate, lentivirus vif genes. J Virol 1995; 69:4166-72; PMID:7769676
71. Etienne L, Hahn BH, Sharp PM, Matsen FA, Emerman M. Gene loss and adaptation to hominids underlie the ancient origin of HIV-1. Cell Host Microbe 2013; 14:85-92; PMID:23870316; http://dx.doi.org/10.1016/j.chom.2013.06.002
72. Tompa P. Intrinsically disordered proteins: a 10-year recap. Trends Biochem Sci 2012; 37:509-16; PMID:22989858; http://dx.doi.org/10.1016/j.tibs.2012.08.004
73. Kovacs D, Tompa P. Diverse functional manifestations of intrinsic structural disorder in molecular chaperones. Biochem Soc Trans 2012; 40:963-8; PMID:22988848; http://dx.doi.org/10.1042/BST20120108
74. Xue B, Mizianty MJ, Kurgan L, Uversky VN. Protein intrinsic disorder as a flexible armor and a weapon of HIV-1. Cell Mol Life Sci 2012; 69:1211-59; PMID:22033837; http://dx.doi.org/10.1007/s00018-011-0859-3
75. De Guzman RN, Wu ZR, Stalling CC, Pappalardo L, Borer PN, Summers MF. Structure of the HIV-1 nucleocapsid protein bound to the SL3 psi-RNA recognition element. Science 1998; 279:384-8; PMID:9430589; http://dx.doi.org/10.1126/science.279.5349.384
76. Paul I, Cui J, Maynard EL. Zinc binding to the HCCH motif of HIV-1 virion infectivity factor induces a conformational change that mediates protein-protein interactions. Proc Natl Acad Sci U S A 2006; 103:18475-80; PMID:17132731; http://dx.doi.org/10.1073/pnas.0604150103
77. Houzet L, Morichaud Z, Didierlaurent L, Muriaux D, Darlix JL, Mougel M. Nucleocapsid mutations turn HIV-1 into a DNA-containing virus. Nucleic Acids Res 2008; 36:2311-9; PMID:18296486; http://dx.doi.org/10.1093/nar/gkn069
78. Thomas JA, Bosche WJ, Shatzer TL, Johnson DG, Gorelick RJ. Mutations in human immunodeficiency virus type 1 nucleocapsid protein zinc fingers cause premature reverse transcription. J Virol 2008; 82:9318-28; PMID:18667500; http://dx.doi.org/10.1128/JVI.00583-08
79. Camaur D, Trono D. Characterization of human immunodeficiency virus type 1 Vif particle incorporation. J Virol 1996; 70:6106-11; PMID:8709234
80. Fouchier RA, Simon JH, Jaffe AB, Malim MH. Human immunodeficiency virus type 1 Vif does not influence expression or virion incorporation of gag-, pol-, and env-encoded proteins. J Virol 1996; 70:8263-9; PMID:8970945
81. Paillart JC, Skripkin E, Ehresmann B, Ehresmann C, Marquet R. In vitro evidence for a long range pseudoknot in the 5′-untranslated and matrix coding regions of HIV-1 genomic RNA. J Biol Chem 2002; 277:5995-6004; PMID:11744696; http://dx.doi.org/10.1074/jbc.M108972200
82. Dardel F. MC-Fit: using Monte-Carlo methods to get accurate confidence limits on enzyme parameters. Comput Appl Biosci 1994; 10:273-5; PMID:7922682
83. Piotto M, Saudek V, Sklenár V. Gradient-tailored excitation for single-quantum NMR spectroscopy of aqueous solutions. J Biomol NMR 1992; 2:661-5; PMID:1490109; http://dx.doi.org/10.1007/BF02192855
84. Weigelt J. Single scan, sensitivity- and gradient-enhanced TROSY for multidimensional NMR experiments. J Am Chem Soc 1998; 120:10778-9; http://dx.doi.org/10.1021/ja982649y
85. Ivanyi-Nagy R, Lavergne JP, Gabus C, Ficheux D, Darlix JL. RNA chaperoning and intrinsic disorder in the core proteins of Flaviviridae. Nucleic Acids Res 2008; 36:712-25; PMID:18033802; http://dx.doi.org/10.1093/nar/gkm1051
86. Andrade MA, Chacón P, Merelo JJ, Morán F. Evaluation of secondary structure of proteins from UV circular dichroism spectra using an unsupervised learning neural network. Protein Eng 1993; 6:383-90; PMID:8332596; http://dx.doi.org/10.1093/protein/6.4.383